Overview

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Status:
Temporarily not available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Details

Lead Sponsor:

Bennett, James P., Jr., M.D., Ph.D.

Collaborators:

University of Nebraska
University of Pittsburgh

Treatments:

Pramipexole